Clinical Significance of Bmi1 Expression in Inflammatory Bowel Disease

• Published in: Oncology Vol. 93 Suppl 1; p. 20
• Main Authors: Yamada, Mitsunari, Sakurai, Toshiharu, Komeda, Yoriaki, Nagai, Tomoyuki, Kamata, Ken, Minaga, Kosuke, Yamao, Kentaro, Takenaka, Mamoru, Hagiwara, Satoru, Matsui, Shigenaga, Watanabe, Tomohiro, Nishida, Naoshi, Kashida, Hiroshi, Kudo, Masatoshi
• Format: Journal Article
• Language: English
• Published: Switzerland 01.01.2017
• Subjects: Adult; Colitis, Ulcerative - enzymology; Colitis, Ulcerative - pathology; Colorectal Neoplasms - enzymology; Colorectal Neoplasms - pathology; Crohn Disease - enzymology; Crohn Disease - pathology; Cytokines - biosynthesis; Female; Humans; Intestinal Mucosa - enzymology; Intestinal Mucosa - pathology; Male; Middle Aged; Mitogen-Activated Protein Kinase 7 - biosynthesis; Up-Regulation; Colitis-associated cancer; Gankyrin; Infliximab; Stress response; Tumor necrosis factor
• ISSN: 1423-0232
• DOI: 10.1159/000481225

Although the stem cell marker Bmi1 is overexpressed in many malignancies, its role in inflammation-associated cancer is unclear. Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel disease (IBD). To assess the involvement of Bmi1 in the development of CAC, we analyzed the gene expression of colon tissues collected from 111 patients with IBD and CAC. In the colonic mucosa of patients with ulcerative colitis, the expression of Bmi1 correlated significantly with the expression of inflammatory cytokines such as IL-6, IL-17, IL-23, and tumor necrosis factor α (TNF-α). In the colonic mucosa of patients with Crohn's disease, the expression of Bmi1 correlated significantly with the expression of TNF-α and IL-23. The expression of Bmi1 was enhanced in the colonic mucosae of refractory IBD, suggesting that Bmi1 expression might be related to increased cancer risk. In addition, patients with high Bmi1 expression showed significantly lower response rates upon subsequent anti-TNF-α therapy as compared to patients with low Bmi1 expression. In human CAC specimens, the expression of Bmi1 was upregulated in nontumor tissues as well as tumors. Bmi1 expression is related to a refractory clinical course of IBD and upregulated in refractory IBD and CAC. Measurement of Bmi1 expression is a promising approach for the advanced treatment and personalized management of IBD patients.